(Q39669033)

13 September 2017

title

Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma (English)

1 reference

13 September 2017

1 reference

Richeng Jiang

1

1 reference

13 September 2017

Ziliang Jin

2

1 reference

13 September 2017

Zhujun Liu

3

1 reference

13 September 2017

Leina Sun

4

1 reference

13 September 2017

Liuchun Wang

5

1 reference

13 September 2017

Kai Li

6

1 reference

13 September 2017

publication date

1 December 2011

1 reference

Molecular Diagnosis and Therapy

13 September 2017

published in

1 reference

13 September 2017

volume

15

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

347-352

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256470

13 September 2017

exact match

0 references

cites work

Non–Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

STAT signaling in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

New and old functions of STAT3: a pivotal target for individualized treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

The Catalogue of Somatic Mutations in Cancer (COSMIC)

21 January 2018

1 reference

12 December 2020

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

1 reference

12 December 2020

Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)

1 reference

12 December 2020

EGFR dependent expression of STAT3 (but not STAT1) in breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256470

1 reference

13 September 2017

1 reference